Please use this identifier to cite or link to this item: https://www.um.edu.mt/library/oar/handle/123456789/57543
Title: A case of severe relapsing sulphonylurea-induced hypoglycaemia
Authors: Mifsud, Simon
Schembri, Emma Louise
Fava, Stephen
Keywords: Hypoglycemia -- Case studies
Hypoglycemic agents
Blood sugar monitoring
Diabetes -- Complications
Diabetes Mellitus, Type 2
Insulin
Kidneys -- Diseases -- Patients -- Care
Issue Date: 2019
Publisher: BMJ
Citation: Mifsud, S., Schembri, E. L., & Fava, S. (2019). A case of severe relapsing sulphonylurea-induced hypoglycaemia. BMJ Case Reports CP, 12(12).
Abstract: The authors report a case of a 64-year-old woman who was diagnosed with severe relapsing sulphonylurea-induced hypoglycaemia. Sulphonylureas are frequently used in patients with type 2 diabetes mellitus. They promote insulin secretion independent of the prevailing glucose level and thus are associated with an increased risk of hypoglycaemia. In patients with adequate renal function, gliclazide's effect lasts 10-24 hours and it is usually completely eliminated within 144 hours postdose. Since our patient suffered from chronic kidney disease, gliclazide's effect was prolonged and she was experiencing spontaneous hypoglycaemic episodes up to 21 days postomission of gliclazide. This case highlights two important aspects. Primarily, the prolonged effect of sulphonylureas in patients with impaired renal function, hence highlighting the need to be cautious prior to prescribing sulphonylureas in such patients. Secondly, the importance of prolonged observation of patients on sulphonylureas even after the initial hypoglycaemic event is corrected, due to the extended effects of such drugs.
URI: https://www.um.edu.mt/library/oar/handle/123456789/57543
Appears in Collections:Scholarly Works - FacM&SMed

Files in This Item:
File Description SizeFormat 
A_case_of_severe_relapsing_sulphonylurea_induced_hypoglycaemia_2019.pdf
  Restricted Access
556.13 kBAdobe PDFView/Open Request a copy


Items in OAR@UM are protected by copyright, with all rights reserved, unless otherwise indicated.